Pasar al contenido principal

INTERACCION DE LAS CELULAS MADRE PLURIPOTENTES INDUCIDAS (IPSCS) CON EL SISTEMA INMUNE EN MODELO EQUINO: UN PASO NECESARIO EN EL DESARROLLO Y TRASLACION DE TERAPIAS AVANZADAS

PID2020-116352GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The immunomodulation–immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility

  • Cequier, Alina
  • Vázquez, Francisco José
  • Romero, Antonio
  • Vitoria, Arantza
  • Bernad, Elvira
  • García-Martínez, Mirta
  • Gascón, Isabel
  • Barrachina, Laura
  • Rodellar, Clementina
The immunomodulatory properties of equine mesenchymal stem cells (MSCs) are important for their therapeutic potential and for their facilitating role in their escape from immune recognition, which may also be influenced by donor–recipient major histocompatibility complex (MHC) matching/mismatching and MHC expression level. Factors such as inflammation can modify the balance between regulatory and immunogenic profiles of equine MSCs, but little is known about how the exposure to the immune system can affect these properties in equine MSCs. In this study, we analyzed the gene expression and secretion of molecules related to the immunomodulation and immunogenicity of equine MSCs, either non-manipulated (MSC-naive) or stimulated by pro-inflammatory cytokines (MSC-primed), before and after their exposure to autologous or allogeneic MHC-matched/-mismatched lymphocytes, either activated or resting. Cytokine priming induced the immunomodulatory profile of MSCs at the baseline (MSCs cultured alone), and the exposure to activated lymphocytes further increased the expression of interleukin 6 (IL6), cyclooxygenase 2, and inducible nitric oxide synthase, and IL6 secretion. Activated lymphocytes were also able to upregulate the regulatory profile of MSC-naive to levels comparable to cytokine priming. On the contrary, resting lymphocytes did not upregulate the immunomodulatory profile of equine MSCs, but interestingly, MSC-primed exposed to MHC-mismatched lymphocytes showed the highest expression and secretion of these mediators, which may be potentially linked to the activation of lymphocytes upon recognition of foreign MHC molecules. Cytokine priming alone did not upregulate the immunogenic genes, but MSC-primed exposed to activated or resting lymphocytes increased their MHC-I and MHC-II expression, regardless of the MHC-compatibility. The upregulation of immunogenic markers including CD40 in the MHC-mismatched co-culture might have activated lymphocytes, which, at the same time, could have promoted the immune regulatory profile aforementioned. In conclusion, activated lymphocytes are able to induce the equine MSC regulatory profile, and their effects seem to be additive to the priming action. Importantly, our results suggest that the lymphocyte response against MHC-mismatched MSC-primed would promote further activation of their immunomodulatory ability, which eventually might help them evade this reaction. Further studies are needed to clarify how these findings might have clinical implications in vivo, which will help developing safer and more effective therapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility: in vivo study in the horse

  • Cequier, Alina
  • Vázquez, Francisco José
  • Vitoria, Arantza
  • Bernad, Elvira
  • Fuente, Sara
  • Serrano, María Belén
  • Zaragoza, María Pilar
  • Romero, Antonio
  • Rodellar, Clementina
  • Barrachina, Laura
The effectiveness and safety of allogeneic mesenchymal stem/stromal cells (MSCs) can be affected by patient’s immune recognition. Thus, MSC immunogenicity and their immunomodulatory properties are crucial aspects for therapy. Immune responses after allogeneic MSC administration have been reported in different species, including equine. Interactions of allogenic MSCs with the recipient’s immune system can be influenced by factors like matching or mismatching for the major histocompatibility complex (MHC) between donor-recipient, and by the levels of MHC expression in MSCs. The latter can vary upon MSC inflammatory exposure or differentiation, such as chondrogenic induction, making both priming and differentiation interesting therapeutic strategies. This study investigated the systemic in vivo immune cellular response against allogeneic equine MSCs in these situations. Either MSCs in basal conditions (MSC-naïve), pro-inflammatory primed (MSC-primed) or chondrogenically differentiated (MSC-chondro) were repeatedly administered subcutaneously into autologous, MHC-matched or MHC-mismatched allogeneic equine recipients. At different time-points after each administration, lymphocytes were obtained from recipient horses and exposed in vitro to the same type of MSCs to assess the proliferative response of different T cell subsets (cytotoxic, helper, regulatory), B cells, and interferon gamma (IFNγ) secretion. Higher proliferative response of helper and cytotoxic T lymphocytes and IFNγ secretion was observed in response to all types of MHC-mismatched MSCs over MHC-matched ones. MSC-primed produced the highest immune response, followed by MSC-naïve, and MSC-chondro. However, MSC-primed activated Treg and had a mild effect on B cells, and the response after their second administration was similar to the first one. On the other hand, both MSC-chondro and MSC-naïve barely induced Treg response but promoted B lymphocyte activation, and proportionally induced a higher cell response after the second administration. In conclusion, both the type of MSC conditioning and the MHC compatibility influenced systemic immune recognition of equine MSCs after single and repeated administrations, but the response was different. Selecting MHC-matched donors would be particularly recommended for MSC-primed and repeated MSC-naïve administrations. While MHC-mismatching in MSC-chondro would be less critical, B cell response should not be ignored. Comprehensively investigating the in vivo immune response against equine allogeneic MSCs is crucial for advancing veterinary cell therapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

MHC compatibility influences the interaction between different types of equine mesenchymal stem/stromal cells and the local immune response

  • Cequier, Alina
  • Serrano, Mª Belén
  • Soler-Monsó, Mª. Teresa
  • Bernad, Elvira
  • Vázquez, Francisco José
  • Vitoria, Arantza
  • Fuente, Sara
  • Zaragoza, Pilar
  • Romero, Antonio
  • Rodellar, Clementina
  • Barrachina, Laura
The allogeneic administration of equine mesenchymal stem/stromal cells (MSCs) has numerous advantages over autologous therapy, but their interactions with the patient's immune system need to be further elucidated. These interactions can be influenced by factors such as the compatibility between donor-receptor for the major histocompatibility complex (MHC) and by the MHC expression levels, which can change under different conditions like inflammatory exposure and chondrogeneic differentiation. In this study, we evaluated the local immune response induced by chondrogeneically differentiated (MSC-chondro), pro-inflammatory primed (MSC-primed) and basal (MSC-naïve) MSCs, and how this response changes the immunomodulatory and immunogenic profiles of MSCs in vivo. Equine MSCs were embedded in alginate scaffolds and subcutaneously implanted into autologous, MHC-matched and MHC-mismatched horses. Scaffolds were recovered at different time-points for histologic and gene expression analyses, and the procedure was repeated to assess the effect of a second administration. Our results suggest that MHC-compatibility may play a key role in attenuating the local immune response induced by MSCs, which may be related to the upregulation of immunomodulatory genes in the three MSC types in vivo. In contrast, when MSCs were administered into MHC-mismatched horses, expression of immunogenic genes was higher across all MSC conditions. Therefore, the conditions in which MSCs are administered may not affect the long-term local immune response, but MHC-matched administration would favour the immune evasion of MSCs, thus being advisable especially when repeated MSC administrations are required. Comprehensively investigating the in vivo immune response against equine allogeneic MSCs is crucial for advancing veterinary cell therapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Generation of equine induced pluripotent stem cells from cells of embryonic, perinatal and adult tissues

  • Barrachina, Laura
  • Ivanovska, Ana
  • Eslami Arshaghi, Tarlan
  • O’Brien, Aisling
  • Cequier, Alina
  • Murphy, Mary
  • Hollinshead, Fiona
  • Rodellar, Clementina
  • Barry, Frank
Background: Regenerative therapies are quickly expanding to application in equine patients because of their importance as sporting and companion animals. Furthermore, aligning with a One Health concept, veterinary medicine offers a unique platform for preclinical studies. While mesenchymal stem/stromal cells (MSCs) therapies are already used in treating horses, strategies involving induced pluripotent stem cells (iPSCs) are poorly developed. iPSCs present great potential for therapy and disease modelling, but their consistent generation in horses requires further investigation into the source of somatic cells and the reprogramming method and conditions. Methods: The reprogramming potential of equine cells from tissues of three developmental origins was compared: prenatal (embryo-derived MSCs, eMSCs), perinatal (cord blood-derived MSCs, CB-MSCs) and adult (articular chondrocytes, ACs). Two reprogramming methods (retroviral, lentiviral) and different culture conditions (serum/serum-free, feeder cells/feeder-free, with/without small molecules) were tested. Pluripotent gene expression was analyzed at different time-points to reveal transcriptomic changes associated with reprogramming. The generated equine iPSCs (eqiPSCs) were characterized by alkaline phosphatase (AP) staining, expression of pluripotent genes and proteins, three-germ layer differentiation (embryoid body) and karyotype. Results: Using a lentiviral vector with serum-free media and feeder cells resulted in the most favorable conditions for eqiPSCs reprogramming, but adding small molecules had a negative effect. Equine CB-MSCs and ACs were only partially reprogrammed and could not be efficiently expanded in culture. Only eMSCs generated putative eqiPSCs that met the cellular, molecular and functional criteria of pluripotent cells. Equine eMSCs showed higher proliferation and basal expression of pluripotent genes compared to CB-MSCs and ACs, and showed the highest upregulation of pluripotent genes along reprogramming. Conclusions: The developmental stage of the starting cell strongly influences their reprogramming potential in equine species. This has been suggested for human and other animal species, but direct comparison of equine cells from prenatal, perinatal and adult sources has not been reported before. Novel preliminary insight into the transcriptomic changes of different equine cell types during reprogramming, and on the effect of different culture conditions, can contribute improving the generation of eqiPSCs. While transgene-free methods are the goal, putative eqiPSCs are critical to enlarge our knowledge on animal iPSC biology.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Derivation of Equine Mesenchymal Stem/Stromal Cells from Induced Pluripotent Stem Cells via the Neural Crest Pathway and Characterisation by Immunophenotype and Tri-Lineage Differentiation

  • Bernad, E.
  • Serrano, B.
  • Vitoria, A.
  • Fuente, S.
  • Romero, A.
  • Vázquez, F. J.
  • Zaragoza, P.
  • Rodellar, C.
  • Cequier, A.
  • Barrachina, L.
Mesenchymal stem/stromal cells (MSCs) hold promise for treating different equine conditions but enter senescence during culture. Using induced pluripotent stem cells (iPSCs) to derive MSC-like cells (iMSCs) can increase cell availability and diminish the need for invasive and repeated tissue harvesting. While human iMSCs are intensively studied, research on equine iMSCs (eqiMSCs) is very limited and has focused on strategies for spontaneous differentiation to obtain these cells. The aim of this study was to obtain MSC-like cells from equine iPSCs (eqiPSCs) by directing their differentiation via the neural crest pathway. The resulting eqiMSCs downregulated pluripotent gene expression compared to originating eqiPSCs, and the majority of lines met most of the standard criteria for tissue-derived MSCs (immunophenotype and tri-lineage differentiation potential). Nevertheless, eqiMSCs showed some differences from primary equine MSCs, possibly due to their different developmental origin, and displayed certain inter-line variability, which might be related to the different kinetics of independent eqiPSC lines. This study demonstrates for the first time that equine MSC-like cells (eqiMSCs) can be derived from eqiPSCs by directing their differentiation through the neural crest pathway. This constitutes an important advancement towards more sustainable sources of therapeutic cells in veterinary medicine and warrants further exploration of the functional characteristics of these novel cells.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Humoral immune response to equine mesenchymal stem/stromal cells (MSCs): MHC compatibility has more influence than inflammatory priming or chondrogenic differentiation

  • Cequier, Alina
  • Romero, Antonio
  • Bernad, Elvira
  • Serrano, Belén
  • Vitoria, Arantza
  • Fuente, Sara
  • Fernández, Irene
  • Zaragoza, Pilar
  • Vázquez, Francisco José
  • Barrachina, Laura
  • Rodellar, Clementina
Background Mesenchymal stem/stromal cells (MSCs) hold great potential for treating various conditions, but their effectiveness and safety in allogeneic therapies can be affected by the recipient's immune response, among other factors. Allogeneic MSC administration has been associated with immune recognition in different species, including horses. These animals are both veterinary patients and translational models, offering valuable insights into how allogeneic MSCs interact with the immune system in vivo. Factors such as inflammation, chondrogenic differentiation, and major histocompatibility complex (MHC) compatibility between donor and recipient can influence immune responses, potentially affecting the feasibility of repeated MSC administrations. This study evaluates the humoral immune response following repeated administration of chondrogenically differentiated (MSC-chondro), pro-inflammatory primed (MSC-primed), and basal (MSC-na & iuml;ve) equine MSCs into autologous, MHC-matched, and MHC-mismatched recipients.Methods Equine MSC-chondro, MSC-primed or MSC-na & iuml;ve were embedded into alginate scaffolds and repeatedly implanted subcutaneously into autologous, MHC-matched or MHC-mismatched allogeneic horse recipients. Serum samples collected before and 1, 3, and 6 weeks after each administration were analysed for cytotoxic allo-antibodies against donor MHC. Recipient sera (neat, 1:2 and 1:16 dilution) were tested against donor-derived target cells using two-stage microcytotoxicity assays.Results Autologous and MHC-matched recipients did not develop antibodies against the MHC of the donor, regardless of the MSC type administered. In contrast, MHC-mismatched horses developed allo-antibodies after the first administration, with a notable increase following the second administration. All the MSC types triggered a humoral immune response in MHC-mismatched recipients, but MSC-chondro provoked the strongest immune recognition.Conclusions Donor-recipient MHC compatibility was more important than inflammatory priming or chondrogenic differentiation of equine MSCs to prevent the development of allo-antibodies. Thus, when donor and recipient are MHC-matched, different types of equine MSCs (MSC-chondro, MSC-primed or MSC-na & iuml;ve) could be administered without producing a humoral response.